XT
TBPH icon

XTX Topco’s Theravance Biopharma TBPH Stock Holding History

XTX Topco’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Buy
16,455
+4,683
+40% +$77.5K ﹤0.01% 2982
2026
Q1 		$191K Sell
11,772
-1,820
-13% -$32.2K ﹤0.01% 2859
2025
Q4 		$254K Sell
13,592
-2,946
-18% -$48.9K 0.01% 2212
2025
Q3 		$241K Buy
+16,538
New +$209K 0.01% 1682
2025
Q2 		– Sell
-19,759
Closed -$176K – 3151
2025
Q1 		$176K Buy
19,759
+3,403
+21% +$31.7K 0.01% 1733
2024
Q4 		$154K Sell
16,356
-4,083
-20% -$37.2K 0.01% 1652
2024
Q3 		$165K Buy
20,439
+5,243
+35% +$45.4K 0.01% 1499
2024
Q2 		$129K Buy
+15,196
New +$137K 0.01% 1360
2022
Q4 		– Sell
-20,410
Closed -$207K – 1498
2022
Q3 		$207K Buy
+20,410
New +$191K 0.05% 757
2021
Q3 		– Sell
-14,269
Closed -$207K – 1049
2021
Q2 		$207K Buy
+14,269
New +$268K 0.07% 549

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

XTX Topco's TBPH Position: Q2 2026 in Review

XTX Topco increased its Theravance Biopharma (TBPH) stake by 40% in Q2 2026, buying an estimated $77.5K and bringing the position to 16,455 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #2982.

XTX Topco first reported a position in TBPH in Q2 2021 and has held it in 10 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • XTX Topco held 16,455 shares of Theravance Biopharma worth $280K as of Q2 2026.
  • XTX Topco bought 4,683 Theravance Biopharma shares in Q2 2026, an estimated $77.5K.
  • Theravance Biopharma made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #2982 holding.
  • XTX Topco first reported a position in Theravance Biopharma in Q2 2021 and has held it in 10 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.